NovaBridge Biosciences (NBP) Other Operating Expenses (2024 - 2025)
NovaBridge Biosciences (NBP) posted quarterly Other Operating Expenses of $32000.0 for Q4 2025, up 420.0% year-over-year from $6153.8 in Q4 2024, and up 100.22% quarter-over-quarter from -$14.5 million in Q3 2025.
Powered by 
Analysis
NovaBridge Biosciences (NBP) Other Operating Expenses (2024 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Other Operating Expenses for 2 consecutive years, with $32000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Operating Expenses rose 420.0% year-over-year to $32000.0; the TTM figure through Dec 2025 stood at -$14.5 million (down 144520.0% YoY), while the FY2025 annual figure was $16000.0, up 245.45% from the prior year.
- Other Operating Expenses advanced to $32000.0 in Q4 2025 per NBP's latest filing, from -$14.5 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $32000.0 in Q4 2025 and bottomed at -$14.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | NovaBridge Biosciences | 199.88 Mn | 199.88 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 32,000.00 |
| Sep 30, 2025 | 4.06 Bn |
| Dec 31, 2024 | -10,000.00 |